UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
NOTE: The new presentation time for Aurinia's presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conferences is 4:00 to 4:30 PM Eastern Time. This event is presentation only. Webcast Details remain the same.
The updated release reads:
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
Aurinia management will host one-on-one meetings with investors and will host a presentation on Tuesday, April 16, from 4:00 to 4:30 PM Eastern Time. A live webcast of the session will be available on the investor section of Aurinia's website, which can be found here.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company's head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.
Acadia Pharmaceuticals Inc. today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize...
BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference 2024 on Tuesday, May 14, 2024 at 11:00 am Eastern Time.
The live webcast...
Xavier University of Louisiana (Xavier), a leading undergraduate institution in preparing Black students to successfully complete medical school, has announced continued progress with Ochsner Health (Ochsner), the Gulf South's leading academic...
CareDx, Inc. ? The Transplant Companytm focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers ? today announced it will report financial...
biote Corp. ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement...
MorphoSys AG reports results for the first quarter of 2024.
"The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first half of 2024. The acceptance period for the acquisition is currently...
